Ipamorelin Dosage Guide: GHRP, Reconstitution Protocol & Half-Life Research

Ipamorelin dosage guide: 100–300 mcg dosing, reconstitution table for 2mg and 5mg vials, half-life ~2 hours, pulsatile GH mechanism, and CJC-1295 stack context.

TL;DR

• Ipamorelin is a selective growth hormone releasing peptide (GHRP) that stimulates pulsatile GH release without significant cortisol or prolactin elevation
• Typical research dose: 100–300 mcg per injection, 2–3× daily
• Standard reconstitution: 2 mg vial + 2 mL BAC water = 1,000 mcg/mL
• At 1,000 mcg/mL, a 200 mcg dose = 0.2 mL = 20 units on a U-100 syringe
• Half-life ~2 hours — fasted administration is required for maximal GH pulse
• Calculate your Ipamorelin dose →

Disclaimer: Ipamorelin is not FDA-approved for human use. For educational and research purposes only — not medical advice.

Ipamorelin is a pentapeptide GHRP (growth hormone releasing peptide) and ghrelin receptor agonist that stands out from earlier GHRPs (GHRP-2, GHRP-6) due to its selectivity — it stimulates GH release with minimal effect on cortisol or prolactin. Reconstitution from lyophilized powder uses bacteriostatic water, and accurate unit calculations depend entirely on vial size and dilution volume. Use the pre-filled calculator or consult the table below.

How Many Units Is an Ipamorelin Dose?

Ipamorelin vials are most commonly supplied as 2 mg or 5 mg lyophilized powder. The reconstitution volume determines concentration and therefore the draw volume per dose.

All unit values assume a standard U-100 insulin syringe (100 units = 1 mL).

The most practical setup for a 200 mcg dose is the 2 mg + 2 mL reconstitution (1,000 mcg/mL), which gives exactly 20 units — a clean, easy-to-read mark on a U-100 syringe. For higher-frequency protocols (3× daily), a 5 mg vial reconstituted in 5 mL keeps the same 1,000 mcg/mL concentration while extending the volume across more doses.

Pre-filled Ipamorelin calculator: 2mg / 2mL / 200mcg →

Typical Ipamorelin Research Doses and Timing

The GHRP dosing framework differs fundamentally from most peptides because efficacy depends not just on dose but on the hormonal environment at time of injection. GH release is pulsatile and regulated by a push-pull balance between GHRH (growth hormone releasing hormone, which stimulates) and somatostatin (which suppresses). Insulin, glucose, and free fatty acids all affect somatostatin tone — meaning fed states significantly blunt the GH response to a GHRP injection.

100 mcg is the low-threshold dose used in conservative research protocols. In some early research, 100 mcg was sufficient to elicit measurable GH pulses in fasted subjects. However, the dose-response curve for GHRPs is not linear: the GH release response increases meaningfully from 100 to 200–300 mcg, after which there is a near-plateau due to receptor saturation.

200 mcg is the most widely used reference dose in the literature. It represents a meaningful GH pulse trigger while staying well below the receptor saturation threshold. A 2 mg vial reconstituted in 2 mL gives exactly 10 doses at 200 mcg, making vial logistics straightforward for 10-day research intervals.

300 mcg is the upper boundary for most published Ipamorelin protocols. This dose is used in protocols targeting maximal GH pulse amplitude. Beyond 300 mcg per injection, additional GH release diminishes relative to the dose increase, and there is no established benefit in the literature for exceeding this threshold with Ipamorelin specifically.

Injection frequency reflects the half-life: with a ~2-hour half-life, Ipamorelin is cleared rapidly. The dominant research protocol is 2–3 injections per day, each administered in a fasted state. Common windows are:

• Upon waking (fasted overnight)
• Pre-training (2+ hours after the last meal)
• Before sleep (2–3 hours after the last meal)

The sleep window is particularly studied because endogenous GH secretion is highest during slow-wave sleep (SWS), and an Ipamorelin dose administered before sleep may amplify this natural peak.

Half-Life, GH Pulsatility, and Why Fasting Matters

Ipamorelin has an estimated half-life of approximately 2 hours based on pharmacokinetic data. This short half-life means plasma levels peak within 15–30 minutes of injection and fall to near-zero within 6 hours. The GH pulse triggered by each injection follows a similar rapid kinetic.

This pharmacology has two direct implications for research design:

1. Pulse amplitude vs. tonic elevation. Unlike GH replacement therapy (which produces sustained, non-pulsatile elevation), Ipamorelin produces discrete GH pulses that more closely mimic endogenous GH secretory physiology. Pulsatile GH secretion is associated with better preservation of GH receptor sensitivity over time. Protocols designed to study IGF-1 accumulation or anabolic signaling must account for the fact that IGF-1 rises gradually in response to cumulative GH exposure — a single pulse does not produce a detectable IGF-1 spike within hours.

2. Somatostatin suppression is required. Somatostatin (SRIF) is the primary physiological inhibitor of GH release. Any factor that elevates somatostatin — food intake, insulin, glucose — will blunt the GH response to Ipamorelin substantially. Research in this area has confirmed that the same Ipamorelin dose given in fasted vs. fed states produces meaningfully different GH area-under-curve values. The practical rule: wait at least 2 hours after eating before administering, and avoid food for at least 30–60 minutes post-injection.

Use the half-life calculator to model the Ipamorelin plasma decay curve and optimize injection timing relative to training sessions or sleep windows.

Ipamorelin + CJC-1295 Stack Context

Ipamorelin is most commonly stacked with CJC-1295 — either the DAC (Drug Affinity Complex) version or the non-DAC version (also called Modified GRF 1-29 or Mod GRF 1-29). The rationale for this combination is mechanistic complementarity:

• Ipamorelin is a GHRP that acts on the ghrelin receptor to stimulate GH secretion and suppress somatostatin
• CJC-1295 is a GHRH analog that acts on the GHRH receptor to amplify the GH-releasing signal

These two compounds act on different receptors via different pathways, and when combined, they produce a synergistic GH pulse that is significantly larger than either compound alone. Research models have shown the combination produces GH AUC values substantially higher than additive effects would predict.

The non-DAC + Ipamorelin combination is preferred in research contexts where pulsatility is a variable of interest. CJC-1295 DAC maintains a sustained GH-elevated baseline which is better suited for protocols studying cumulative IGF-1 accumulation or body composition changes over multi-week periods.

Ipamorelin and CJC-1295 can be mixed in the same syringe for co-injection — this is standard practice in the literature. For reconstitution details of both compounds, use the reconstitution calculator. See the full compound entry at /database/ipamorelin.

Storage, Stability, and Injection Technique

Lyophilized Ipamorelin powder is stable at -20°C for long-term storage. Refrigerator storage (4°C) is acceptable for vials that will be used within 60–90 days. Like most lyophilized peptides, it is sensitive to heat and UV light — store in a light-protected container.

Reconstituted Ipamorelin in bacteriostatic water should be stored at 4°C and used within 4–6 weeks. Label each vial with the reconstitution date, concentration, and number of doses remaining. Never freeze the reconstituted solution.

Injection site: Subcutaneous injection is standard for Ipamorelin in research. The abdomen (periumbilical region, avoiding the 2-inch radius around the navel) is the most common site. Rotate injection sites to prevent localized lipodystrophy over long protocols.

Needle size: Insulin syringes (28–31 gauge, 0.5" length) are appropriate for subcutaneous peptide injection. Inject at a 45° angle in lean subjects and 90° in subjects with adequate subcutaneous adipose tissue.

Frequently Asked Questions

Q: What is the correct Ipamorelin dose for GH research? A: Published protocols most consistently use 200–300 mcg per injection administered 2–3 times daily in fasted states. The 200 mcg dose is the most common starting reference point and produces measurable GH pulses in animal models without significant cortisol or prolactin elevation — Ipamorelin's key selectivity advantage over earlier GHRPs. Using the standard 2 mg + 2 mL reconstitution (1,000 mcg/mL), 200 mcg = 20 units on a U-100 syringe.

Q: Why does Ipamorelin not elevate cortisol or prolactin like GHRP-2 and GHRP-6? A: Ipamorelin's selectivity is the defining characteristic that distinguishes it from earlier generation GHRPs. GHRP-2 and GHRP-6 activate not only the GH secretagogue receptor (GHS-R1a) but also off-target receptors that mediate cortisol (via ACTH stimulation) and prolactin release. Ipamorelin was specifically developed to have high selectivity for GHS-R1a, avoiding these off-target activations. This makes it more useful for research where clean GH pulse elicitation without HPA axis confounding is required.

Q: How does the Ipamorelin half-life affect research protocol design? A: The ~2-hour half-life means each injection produces a discrete, rapidly-cleared GH pulse. This is valuable for research designs that want to study pulsatile GH kinetics, but it means the compound is fully cleared between doses in a 3× daily protocol. For protocols where sustained IGF-1 elevation is the goal, Ipamorelin is typically paired with a GHRH analog (CJC-1295) that has a longer half-life, providing a baseline elevation that each Ipamorelin injection amplifies.

Q: Can Ipamorelin be mixed in the same syringe as CJC-1295? A: Yes — co-injection is standard in the research literature. Both peptides are reconstituted separately in BAC water, then the desired doses are drawn from each vial into the same insulin syringe for a single subcutaneous injection. This approach is used because the two compounds act synergistically via different receptor mechanisms. Ensure both reconstituted solutions are at the same temperature before mixing, and use the combined solution promptly rather than storing a pre-mixed syringe.

Ready to calculate your Ipamorelin dose?

→ Open Ipamorelin in the Reconstitution Calculator

→ View Ipamorelin in the Compound Database

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions